These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 28673587)

  • 1. Bariatric surgery may reduce the risk of Alzheimer's diseases through GLP-1 mediated neuroprotective effects.
    Keshava HB; Mowla A; Heinberg LJ; Schauer PR; Brethauer SA; Aminian A
    Med Hypotheses; 2017 Jul; 104():4-9. PubMed ID: 28673587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery.
    Mingrone G; Castagneto-Gissey L
    Diabetes Metab; 2009 Dec; 35(6 Pt 2):518-23. PubMed ID: 20152737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuro-modulation and bariatric surgery for type 2 diabetes mellitus.
    Spector D; Shikora S
    Int J Clin Pract Suppl; 2010 Feb; (166):53-8. PubMed ID: 20377665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives.
    Scheen AJ; De Flines J; De Roover A; Paquot N
    Diabetes Metab; 2009 Dec; 35(6 Pt 2):537-43. PubMed ID: 20152741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
    Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal peptide changes after bariatric and minimally invasive surgery: Relation to diabetes remission.
    Castagneto Gissey L; Casella Mariolo J; Mingrone G
    Peptides; 2018 Feb; 100():114-122. PubMed ID: 29412812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?
    Amouyal C; Andreelli F
    J Diabetes Res; 2016; 2016():5908656. PubMed ID: 27382574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery.
    Larraufie P; Roberts GP; McGavigan AK; Kay RG; Li J; Leiter A; Melvin A; Biggs EK; Ravn P; Davy K; Hornigold DC; Yeo GSH; Hardwick RH; Reimann F; Gribble FM
    Cell Rep; 2019 Feb; 26(6):1399-1408.e6. PubMed ID: 30726726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease.
    Yildirim Simsir I; Soyaltin UE; Cetinkalp S
    Diabetes Metab Syndr; 2018 May; 12(3):469-475. PubMed ID: 29598932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.
    Torekov SS; Madsbad S; Holst JJ
    Obes Rev; 2011 Aug; 12(8):593-601. PubMed ID: 21401851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
    Madsbad S
    Diabetes Obes Metab; 2014 Jan; 16(1):9-21. PubMed ID: 23617798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ileal Interposition in Rats with Experimental Type 2 Like Diabetes Improves Glycemic Control Independently of Glucose Absorption.
    Jurowich CF; Otto C; Rikkala PR; Wagner N; Vrhovac I; Sabolić I; Germer CT; Koepsell H
    J Diabetes Res; 2015; 2015():490365. PubMed ID: 26185767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
    Calsolaro V; Edison P
    CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of GLP-1 in the Metabolic Success of Bariatric Surgery.
    Hutch CR; Sandoval D
    Endocrinology; 2017 Dec; 158(12):4139-4151. PubMed ID: 29040429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
    João AL; Reis F; Fernandes R
    Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.